Sihuan Pharmaceutical Holdings Group Ltd
HKEX:460
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sihuan Pharmaceutical Holdings Group Ltd
Net Income (Common)
Sihuan Pharmaceutical Holdings Group Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sihuan Pharmaceutical Holdings Group Ltd
HKEX:460
|
Net Income (Common)
¥179.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Net Income (Common)
¥5.6B
|
CAGR 3-Years
29%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Net Income (Common)
¥8.1B
|
CAGR 3-Years
28%
|
CAGR 5-Years
5%
|
CAGR 10-Years
13%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Net Income (Common)
¥5.2B
|
CAGR 3-Years
20%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
6%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Net Income (Common)
¥6.8B
|
CAGR 3-Years
23%
|
CAGR 5-Years
14%
|
CAGR 10-Years
33%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Net Income (Common)
¥3.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
244%
|
CAGR 10-Years
N/A
|
|
Sihuan Pharmaceutical Holdings Group Ltd
Glance View
Sihuan Pharmaceutical Holdings Group Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 4,282 full-time employees. The company went IPO on 2010-10-28. The firm is mainly engaged in the research and development, manufacture and sales of pharmaceutical products in China. Its products are applicable in cardio-cerebral vascular (CCV) system, central nervous system, metabolism, oncology and anti-infective fields. Its CCV products include Kelinao, Anjieli and Oudimei, among others. Its non-CCV products include Ren’Ao, Metronidazole and Clindamycin, among others.
See Also
What is Sihuan Pharmaceutical Holdings Group Ltd's Net Income (Common)?
Net Income (Common)
179.7m
CNY
Based on the financial report for Dec 31, 2025, Sihuan Pharmaceutical Holdings Group Ltd's Net Income (Common) amounts to 179.7m CNY.
What is Sihuan Pharmaceutical Holdings Group Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-18%
